Contact Us   |   Sign In   |   Join CAHR
Market Access 201 - May 30, 2019
Share |


Market Access 201


Thursday, May 30th, 2019
  Toronto Airport Marriott Hotel
  901 Dixon Road, Toronto ON, M9W 1J5

7:45am - 4:30pm


CAHR Member: $860  |  Non-Member: $995  | 

Students / not-for-profit patient groups / public sector: $75*

Canadian Perspectives on Value: Is our System Helping or Hindering Innovation?

Join us for a day of learning and networking that will include the views of industry experts, payers, decision-makers, patient organizations, and others, on topics of direct importance to your success.



Registration and Breakfast




Mike Leo
(President of the Canadian Association for Healthcare Reimbursement and Director of Market Access & Public Affairs at CSL Behring), and Bill Dempster, (Director or Education and Events for CAHR and CEO of 3Sixty Public Affairs).


Keynote Speaker
Janet Yale, President and CEO, The Arthritis Society

Our morning keynote speaker will present a patient and health charity perspective on access to prescription medicines in the context of Canada’s dynamic political and policy environment.



Proposed Changes at the Patented Medicine Prices Review Board (PMPRB)

Moderator Joan McCormick (Principal, Price Regulation Consulting at IQVIA)

Tanya Potashnik (Director, Policy and Economic Analysis, PMPRB)

Durhane Wong-Rieger (President and CEO, Canadian Organization for Rare Disorders)

Barb Jaszewski (Principal Consultant, Amaris)


Our panelists will provide an update on activities at the PMPRB, as well as patient perspectives on the proposed changes, and a global view on how these changes could affect Canada’s position in the world of pharmaceutical research and commercialization.


Networking Break




A Conversation with Dr. Brian O’Rourke, President and CEO, Canadian Agency for Drugs and Technologies in Health (CADTH)

In conversation with Ferg Mills, Vice President of CAHR and Director at Innomar
Strategies, Dr. O’Rourke will reflect on ten years of leadership and experience navigating the complex world of drug policy at the very highest levels. Our audience can expect a frank and informative discussion of the major strategic issues facing public drug plans and other elements of the health care system, and how manufacturers can best understand CADTH’s strategic vision.




Opportunity Knocks: Paying for Highly Effective Tissue-Agnostic Oncology Therapies
Moderator Olaf Koester (OK Consulting)
Scott Gavura (Director of Pharmaceutical Services, Cancer Care Ontario),
Dr. Jean-Eric Tarride (Director of the Centre for Health Economics and Policy Analysis, McMaster University)
Julian Nam (Access Manager, Hoffmann-La Roche Ltd).

Tissue-agnostic treatments target specific tumour mutations, regardless of the organ in which the tumour is located. The pan-Canadian Oncology Drug Review (pCODR) has just received its first submission for such a drug, so the issue is already urgent. Realizing the clinical potential of these treatments will require an extensive rethinking of both value assessment and contracting. Our experts will reflect on these questions and others from the viewpoints of the manufacturer, the health technology assessment (HTA) analyst and the public payer.







Keynote Speaker:
Sylvie Bouchard (Director of Medicines, Institut national d'excellence en santé et services sociaux or INESSS)

Over the last couple of years, INESSS has very actively updated its processes and evidence requirements, seeking to emphasize patient-centric approaches and to align more closely with CADTH and Health Canada. Mme. Bouchard will provide our audience with an update on those changes, discussing the importance of the Life Science Strategy 2017-2027 document published by the Ministry.




Shifting Sands: Private Insurance In Canada
Moderator Bennett Lee (Head of Market Access, Sanofi Genzyme Canada)
Ned Pojskic (Pharmacy and Health Provider Relations, Green Shield Canada)
Daria O’Reilly (Lead Health Economist, Telus Health)
Joan Weir (Director, Health and Disability Policy, CHLIA)

Private insurers in Canada are under unprecedented pressures from plan sponsors and other stakeholders as they try to deal with the utilization of highly-effective but high-cost drugs. Add to that the discussions of national pharmacare and the proposed changes at the PMPRB and you have a great deal of uncertainty. Our panelists will offer their perspectives on how the industry is dealing with these challenges.


Networking Break




Accelerating Access to Drugs and Devices through R2D2
Moderator Connie Wong (Senior Reimbursement Consultant, Medtronic)
Anne Tomalin (President, TPI Reg) Murray Krahn (Director, Toronto Health Economics and Technology Assessment) Hamid Sadri (Director, Health Economics and Outcomes Research, Medtronic)

Alignment and harmonization of processes between regulators and reimbursement authorities has been a major theme of policy change for the last year. Our panelists will discuss the potential for accelerated access through these new pathways, and offer guidance to submitters for how to best take advantage of them.

16:00 Executives Roundtable
Moderator Wendy Morton (Associate Director, National Policy, Merck Canada)
Bob McLay (General Manager, Sobi Canada Inc.)
Marina Vasiliou (Managing Director, Biogen)
Ben Faienza (Country Representative, UCB Pharmaceuticals)

Delivering innovation and improving patient outcomes in a volatile reimbursement and regulatory environment requires special skills. Our panel of company leaders will reflect on the head-winds they are facing, and the opportunities they see to navigate this complexity and achieve commercial success.

MC wrap-up Close


Hotel Reservations:

Delegates must reserve hotel accommodation directly with Marriott Reservations on or before MAY 17, 2019. Please click here to book online or call 1.800.905.2811 and request the CAHR rate of $239. 

Hotel room rates are subject to all applicable tax and fees, currently 13% Harmonized Sales Tax (HST) and 4% Municipal Accommodation Tax (MAT) + 13% HST (All tax and fees are subject to change without notice).  All rates & pricing are quoted and payable in Canadian funds.



Working towards the Certified Market Access Professional certification? Also plan to attend Market Access 101 on May 29, 2019. Click here for info! 


CAHR reserves the right to cancel or change speakers, content and date without prior notice. We assume no liability for these changes.


Event Cancellation Policy: For cancellations two (2) weeks or more in advance, delegates will receive a 75% refund. For cancellations made less than two (2) weeks in advance, no refunds are given. Delegate substitutions will be accepted at no cost.


Thank you to our event partners!







Membership Software Powered by YourMembership  ::  Legal